

Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL

Orhan Aktas, Alina Smorodchenko, Stefan Brocke, Carmen Infante-Duarte, Ulf Schulze Topphoff, Johannes Vogt, Timour Prozorovski, Susanne Meier, Venera Osmanova, Elena Pohl, Ingo Bechmann, Robert Nitsch, and Frauke Zipp*

*Correspondence: frauke.zipp@unimedizin-mainz.de

<http://dx.doi.org/10.1016/j.neuron.2012.07.016>

(Neuron 46, 421–432; May 5, 2005)

The figure legend to Figure 2A contained incorrectly calculated SEM values given for disability scores (underlined below). Recalculated SEM values are now given in brackets below. This correction has, however, no impact on statistical analysis and the findings reported in this figure.

We apologize to the readers of *Neuron* for any inconvenience this mistake may have caused.

Figure 2. Immunomodulatory Effect and Systemic Distribution of Intracisternal DR5:Fc

(A) T cells and macrophages/microglia cells were isolated from the brain at the onset of the disease (day 7) (mean disability score \pm SEM for DR5:Fc-treated group 2.63 ± 1.31 (**correct SEM: 0.47**); for Fc-treated control group 0.75 ± 0.38 (**correct SEM: 0.32**); $n = 4$ for both groups) and at the time of remission (day 14) (mean disability score \pm SEM at the disease peak for DR5:Fc-treated group 1.95 ± 0.81 [$n = 5$]; for Fc-treated control group 2.92 ± 0.60 [$n = 6$]). Activation markers determined by FACS analysis are given as means with SEM (open bars, treatment with Fc fragment only; filled bars, treatment with DR5:Fc; * $p < 0.05$, Mann-Whitney U-test).